B
BioAtla, Inc. (BCAB)
0.15
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.15
0.00 (0.00%)
BioAtla, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, qattiq o'simta saratonini davolash uchun maxsus va tanlangan antitelalarga asoslangan terapevtik vositalarni ishlab chiqadi. Kompaniyaning etakchi klinik bosqichdagi mahsulot nomzodlari orasida undiferensial pleomorfik sarkoma va mayda hujayrali o'pka saratonini (NSCLC) davolash uchun shartli faol biologik (CAB) antitel-dorivor konjugati (ADC) bo'lgan mecbotaamab vedotin (BA3011); va melanoma va bosh va bo'yinning yassi hujayrali karsinomasi uchun CAB ADC bo'lgan ozuriftamab vedotin (BA3021) mavjud. Kompaniya, shuningdek, melanomani, buyrak hujayrali karsinomani, kolorektal saratonni va NSCLCni davolash uchun sitotoksik T-limfotsit-assotsiatsiyalangan antigen 4 ga qarshi CAB antitelasi bo'lgan Evalstotug (BA3071); adenokarsinomalarni davolash uchun bispesifik nomzod bo'lgan BA3182; o'simtalarni davolash uchun CAB-Nectin-4-ADC bo'lgan BA3361; turli qattiq o'simtalarda ifodalangan oqsil bo'lgan B7-H3 ni maqsad qilib olgan dual-CAB T-hujayrali ingagator bo'lgan BA3142; va CAB-Nectin 4 x CAB-CD3 uchun preklinik nomzodni ishlab chiqmoqda. Kompaniya 2007 yilda tashkil etilgan va uning shtab-kvartirasi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Cathy Chang Ph.D. | Senior Vice President of Research & Development |
| Dr. Eric L. Sievers M.D. | Chief Medical Officer |
| Dr. Gerhard Frey Ph.D. | Senior Vice President of Technology Development |
| Dr. Jay M. Short Ph.D. | Co-Founder, CEO & Chairman |
| Lisa M. Pelton | Accounting Manager |
| Mr. Christian J. Vasquez CPA | CFO & Chief Accounting Officer |
| Ms. Monica Sullivan | Senior Vice President of Intellectual Property & Contracts |
| Ms. Sheri Lydick | Chief Commercial Officer |
| Ms. Susie Melody | Senior Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-02 | 8-K | n5620_8k.htm |
| 2026-01-30 | PREM14A | n5620_x1-prem14a.htm |
| 2026-01-16 | S-3 | d31173ds3.htm |
| 2026-01-15 | DEFA14A | d26857ddefa14a.htm |
| 2026-01-12 | 8-K | bcab-20260109.htm |
| 2025-12-31 | DEFA14A | d21249ddefa14a.htm |
| 2025-12-30 | 8-K | bcab-20251230.htm |
| 2025-12-05 | DEF 14A | n5452_x1-def14a.htm |
| 2025-11-24 | PRE 14A | d830876dpre14a.htm |
| 2025-11-13 | 10-Q | bcab-20250930.htm |